



Pfizer Inc.
235 East 42nd St.
New York, NY 10017

October 13, 2020

Subject: Shortage of Norpace® CR 150 mg and Norpace® CR 100 mg

Dear Healthcare Provider,

The purpose of this letter is to inform you that Norpace CR 150 mg and Norpace CR 100 mg (disopyramide phosphate extended-release capsules) are experiencing manufacturing delays and are out of stock. There is no impact on Norpace (disopyramide phosphate immediate release) capsules.

Product	Current Status	Date Shortage Occurred	Date when shortage is expected to be resolved
Norpace CR 150 mg	Out of stock	August 2020	Unknown
Norpace CR 100 mg	Out of stock	October 2020	Unknown

Pfizer recognizes the importance of Norpace CR for your patients and is making every effort to resolve the manufacturing issue as soon as possible. Currently, we are not able to provide a projected date when Norpace CR might be available.

There is a limited reserve supply of Norpace CR 150 mg and Norpace CR 100 mg available for drop shipment directly through Pfizer to meet critical needs of selected patients. A letter of medical necessity from the treating health care provider is required for drop shipment. Please contact the Pfizer Customer Service Drop Ship Team at: 1(800) 533-4535, option 4,2 or dropships@pfizer.com. In addition, Norpace (disopyramide phosphate immediate release) capsules are currently available.

Healthcare professionals should use their clinical expertise to determine an alternative treatment option for their patients in the interim. Pfizer cannot make recommendations regarding alternative treatments.

Norpace CR is indicated for the treatment of documented ventricular arrhythmias. For additional medical questions on Norpace CR, please contact Pfizer Medical Information 1-800-438-1985. Please see full prescribing information, including Boxed Warnings, available at: <http://labeling.pfizer.com/ShowLabeling.aspx?id=634>

Healthcare providers are encouraged to report adverse events, including product defects, by contacting Pfizer at 1-800-438-1985 or by contacting the FDA at <http://www.fda.gov/Safety/MedWatch> or by calling 1-800-FDA-1088.

Sincerely,

A handwritten signature in black ink, appearing to read "Haq Nawaz", written over a light gray rectangular background.

Haq Nawaz, MD, MPH, MBA, MS
US Medical Affairs
Pfizer Inc.

(c) 2020 Pfizer Inc. All rights reserved.